NIPRIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Nipride, and what generic alternatives are available?
Nipride is a drug marketed by Roche and Exela Pharma and is included in two NDAs.
The generic ingredient in NIPRIDE is sodium nitroprusside. There are one thousand four hundred and seventy-two drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the sodium nitroprusside profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nipride
A generic version of NIPRIDE was approved as sodium nitroprusside by SAGENT PHARMS INC on December 8th, 2016.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NIPRIDE?
- What are the global sales for NIPRIDE?
- What is Average Wholesale Price for NIPRIDE?
Summary for NIPRIDE
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Clinical Trials: | 3 |
| Drug Prices: | Drug price information for NIPRIDE |
| DailyMed Link: | NIPRIDE at DailyMed |
Recent Clinical Trials for NIPRIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Alberta | N/A |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 2 |
| Curt Treu | N/A |
US Patents and Regulatory Information for NIPRIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Roche | NIPRIDE | sodium nitroprusside | INJECTABLE;INJECTION | 017546-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Exela Pharma | NIPRIDE RTU IN SODIUM CHLORIDE 0.9% | sodium nitroprusside | SOLUTION;INTRAVENOUS | 209387-001 | Mar 8, 2017 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Exela Pharma | NIPRIDE RTU IN SODIUM CHLORIDE 0.9% | sodium nitroprusside | SOLUTION;INTRAVENOUS | 209387-002 | Dec 7, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
